Wolters Kluwer Acquires U.S. AI-Enabled Drug Diversion Detection Software

Technology Leader Seeks to Help Tackle Growing Drug Diversion Challenge in the U.S. Wolters Kluwer Health today announced it has signed and completed the acquisition of Invistics Corporation (Invistics), a U.S.-based provider of cloud-based, AI-enabled software for drug diversion detection and controlled substance compliance. Invistics will join the company’s Clinical Surveillance, Compliance & Data Solutions unit, part of Clinical Solutions. Invistics’ solution, Flowlytics, uses predictive analytics to detect illicit diversion of both controlled and non-controlled medications in patient care settings such as hospitals and ambulatory surgery centers. Drug diversion is a growing challenge in the U.S. healthcare system, costing some $70 billion per year. One study estimates 10% to 15% of health professionals will misuse drugs or alcohol at some point in their career, increasing the risk for drug diversion. Drug diversion occurs when a healthcare worker illegally obtains or uses prescription drugs intended for a patient. Flowlytics reconciles drug transactions from purchase to patient and uses AI to rapidly and accurately identify patterns of behavior consistent with drug diversion. A five-year National Institutes of Health-funded study found that Flowlytics detected cases of drug diversion faster and with more efficiency than legacy solutions. In addition to detection, the solution also supports diversion investigation, adjudication, and reporting workflows. “Invis...
Source: EMR and HIPAA - Category: Information Technology Authors: Tags: Health IT Company Healthcare IT Clinical Solutions Clinical Surveillance Compliance & Data Solutions Unit Controlled Substance Compliance Diversion Investigation Drug Diversion Drug Diversion Detection Flowlytics Health IT Acquisitions Source Type: blogs